Why Baudax Bio Shares Trading Higher Today

为什么 Baudax Bio 股票今天交易走高

Benzinga Real-time News · 2023/01/25 00:41

Baudax Bio Inc (NASDAQ:BXRX) announced the outcome of its first interim analysis in a Phase 2 trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.
The trial evaluates three doses of BX1000 to a standard dose of rocuronium and expects to enroll 80 adult patients undergoing elective surgery utilizing total intravenous anesthesia.
Additionally, the trial evaluates the safety and tolerability profile of BX1000 and rocuronium in this patient population.
The pre-planned interim analysis evaluated the intubating conditions for each patient after administering the study drug in a blinded fashion.
All 20 patients were observed to have met the criteria for Good or Excellent intubating conditions at 60 seconds. Nineteen of the subjects were successfully intubated following the assessment at 60 seconds, and the remaining subject followed the assessment at 90 seconds.
Study treatments were generally well tolerated, with no severe or serious adverse events.
The company plans to complete enrollment in the study in Q1 and share the topline results for the study in April 2023.
Price Action: BXRX shares are up 39.40% at $4.39 on the last check Tuesday.

Baudax Bio Inc 纳斯达克股票代码：BXRX）公布了其对接受选择性手术的患者进行神经肌肉阻滞（NMB）的 BX1000 2期试验的首次中期分析结果。
该试验将三剂的 BX1000 与标准剂量的罗库溴铵进行评估，预计将招收 80 名使用全静脉麻醉进行选择性手术的成年患者。
此外，该试验还评估了该患者群体中 BX1000 和 rocuronium 的安全性和耐受性。
预先计划的中期分析评估了每位患者在盲目施用研究药物后的插管状况。
观察到所有20名患者在60秒时均符合插管条件良好或极好的标准。评估后，19名受试者在60秒后成功插管，其余受试者在90秒后接受了评估。
研究治疗通常耐受性良好，没有严重或严重的不良事件。
该公司计划在第一季度完成该研究的注册，并在2023年4月分享该研究的主要结果。
价格走势： 周二的最后一张支票显示，BXRX股价上涨了39.40％，至4.39美元。

译文内容由第三方软件翻译。

以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。

风险及免责提示